Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.73 |
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 3/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19880209 | 0.98 | CASP2 (0.77) | CASP2NAAAMEN1KMT2AFAAH | |
| SCHEMBL17070055 | 0.98 | CASP2 (0.77) | CASP2NAAAMEN1KMT2AFAAH | |
| SCHEMBL23288384 | 0.96 | CASP2 (0.67) | CASP2NAAAMEN1KMT2AFAAH | |
| SCHEMBL7537764 | 0.91 | CASP2 (0.86) | CASP2NAAAMEN1KMT2AFAAH | |
| SCHEMBL14199967 | 0.89 | CASP2 (0.91) | CASP2NAAAMEN1KMT2AFAAH | |
| SCHEMBL22623202 | 0.88 | CASP2 (0.68) | CASP2NAAAFAAHEPHX1HPGD | |
| SCHEMBL19248862 | 0.88 | CASP2 (0.68) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL19249062 | 0.88 | CASP2 (0.68) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL25091844 | 0.88 | CASP2 (0.68) | CASP2NAAAMEN1KMT2AFAAH | |
| SCHEMBL12583601 | 0.86 | CASP2 (0.59) | CASP2NAAAMEN1KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | IL17A, IL15, IL2 | CASP2 629/4885NAAA 4744/4885MEN1 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.